Evidence map›Paper›PMID 24067184›Full record

ArticleHigh altitude medicine & biology2013

Continuous positive airway pressure treatment for acute mountain sickness at 4240 m in the Nepal Himalaya.

Pamela L Johnson, Claire C Johnson, Prasanta Poudyal, Nirajan Regmi, Megan A Walmsley, Buddha Basnyat

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in High altitude medicine & biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04186598 nacompletednot on this mapstarted 2020, after this paper: background citation

Multicenter Randomized Double-Blind Control Trial Evaluating the Utility of Continuous Positive Airway Pressure (CPAP) in the Treatment of High Altitude Pulmonary Edema (HAPE)

TypeinterventionalSponsorCommonSpirit HealthRan2020 to 2023Enrolled64ConditionsContinuous Positive Airway Pressure, High Altitude Pulmonary EdemaArmsCPAP mask system, Nifedipine 30 MG, CPAP mask system without PEEP
NCT04710953 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Comparison of Effectiveness Between Continuous Positive Airway Pressure (CPAP) and Hyperbaric Chamber Ventilation for the Patients of High Altitude Pulmonary Edema (HAPE) When Given in Addition to Standard of care-a Randomized Control Trial

TypeinterventionalSponsorsultan mehmood kamranRan2021 to 2022Enrolled30ConditionsHigh Altitude Pulmonary EdemaArmsContinuous positive airway pressure machine
NCT07148674 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Positive Expiratory Pressure on Acute Mountain Sickness, a Pilot Crossover Trial at 6000 Meters

TypeinterventionalSponsorBiALP - Alpine, Disaster and Wilderness MedicineRan2025 to 2025Enrolled3ConditionsAcute Mountain Sickness (AMS)ArmsPositive Expiratory Pressure (10cmH2O) in hypobaric hypoxia
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. High Altitude Pulmonary Edema Response to Continuous Airway Positive Pressure: A Randomized Controlled Trial: The HAPER CAPER Trial.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025
    Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pamela L Johnson1 David Read Laboratory, University of Sydney , Sydney, NSW Australia .
Claire C Johnson
Prasanta Poudyal
Nirajan Regmi
Megan A Walmsley
Buddha Basnyat
Himalayan Rescue Association · NP

Funding

Wellcome Trust 089276
6 · The paper itself

Abstract

Acute mountain sickness (AMS) is very common at altitudes above 2500 m. There are few treatment options in the field where electricity availability is limited, and medical assistance or oxygen is unavailable or difficult to access. Positive airway pressure has been used to treat AMS at 3800 m. We hypothesized that continuous positive airway pressure (CPAP) could be used under field conditions powered by small rechargeable batteries. Methods Part 1. 5 subjects trekked to 3500 m from 2800 m in one day and slept there for one night, ascending in the late afternoon to 3840 m, where they slept using CPAP 6-7 cm via mask. The next morning they descended to 3500 m, spent the day there, ascended in late afternoon to 3840 m, and slept the night without CPAP. Continuous overnight oximetry was recorded and the Lake Louise questionnaire for AMS administered both mornings. Methods Part 2. 14 trekkers with symptoms of AMS were recruited at 4240 m. All took acetazolamide. The Lake Louise questionnaire was administered, oximetry recorded, and CPAP 6-7 cm was applied for 10-15 min. CPAP was used overnight and oximetry recorded continuously. In the morning the Lake Louise questionnaire was administered, and oximetry recorded for 10-15 min. The equipment used in both parts was heated, humidified Respironics RemStar® machines powered by Novuscell™ rechargeable lithium ion batteries. Oximetry was recorded using Embletta™ PDS. Results Part 1. CPAP improved overnight Sao2 and eliminated AMS symptoms in the one subject who developed AMS. CPAP was used for 7-9 h and the machines operated for >8 h using the battery. Results Part 2. CPAP use improved Sao2 when used for 10-15 min at the time of recruitment and overnight CPAP use resulted in significantly reduced AMS symptoms. Conclusion. CPAP with rechargeable battery may be a useful treatment option for trekkers and climbers who develop AMS.

Indexed as

Continuous Positive Airway PressureAcetazolamideAdultAltitudeAltitude SicknessCarbonic Anhydrase InhibitorsElectric Power SuppliesFemaleHumansMaleMiddle AgedMountaineeringOxygenYoung AdultAcetazolamideCarbonic Anhydrase InhibitorsOxygen

Identifiers

PMID24067184
PMCPMC5206702
OpenAlexW2073340062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.